Japan's Varinos raises US$9.62M to expand fertility genomics testing
What's the deal? Varinos, a Tokyo-based medical startup that uses genomic analysis to assess uterine bacterial environments, has closed a Series D round totalling roughly US$9.62M. The company develops and commercialises a uterine flora test it first brought to market in 2017 — the world's first of its kind.
Mirai Sozou Investments led the equity portion, with new investors Mitsui Chemicals and Yokohama CapitalDealroom has a profile for this one. Try Dealroom → joining. Debt financing came from Resona BankDealroom has a profile for this one. Try Dealroom → as lead lender, alongside Shizuoka BankDealroom has a profile for this one. Try Dealroom →, Shoko Chukin Bank, Joyo Bank, and Higashi Nippon Bank.
Alongside the raise, Varinos overhauled its leadership. Yoshiyuki Sakuraba became chairman, Yoichi Saito took the role of representative director and chief executive officer, and Hidetoshi Hirakawa was named president.
Why now? Demand for the company's flagship uterine flora test has surged. The number of procedures performed under Japan's advanced medical treatment framework tripled between fiscal years 2023 and 2025. The test is now used by more than 400 clinics, with cumulative samples exceeding 50,000.
The fresh capital will fund quality improvements, domestic and international expansion, new product development, and stronger governance. A research contract with Mitsui Chemicals — aimed at developing tests for broader women's health — has already kicked off as the first new initiative.
What could go wrong? Varinos operates in a niche that is clinically promising but still evolving. Uterine microbiome science is young, and widespread insurance reimbursement has not yet arrived — the test currently sits under Japan's "advanced medicine" designation rather than standard coverage. Scaling overseas means navigating different regulatory regimes, and competition from larger diagnostics players could intensify as the field matures.
The signal: Varinos's investor mix — a chemicals conglomerate in Mitsui Chemicals, regional banks, and a local investment fund — reflects a pattern common in Japan's startup ecosystem, where corporate and institutional backers often substitute for the deep VC pools found elsewhere. The round's heavy debt component, with Resona Bank leading alongside four regional lenders, underscores that dynamic. As governments across East Asia pour policy resources into reversing declining birth rates, fertility-adjacent startups with proven clinical traction, like Varinos's 50,000-plus samples processed, are well positioned to attract cross-border interest from both strategic investors and health systems facing the same demographic pressures.
Read more: prtimes.jp
